Research And Collaboration Agreements (Cobimetinib Collaboration To Bristol-Meyers Squibb) (Details) (USD $)
|
12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2013
Glaxo SmithKline [Member]
|
Mar. 31, 2010
Genentech [Member]
|
Mar. 31, 2008
Genentech [Member]
|
Jan. 31, 2007
Genentech [Member]
|
Dec. 31, 2006
Genentech [Member]
|
Dec. 31, 2013
Genentech [Member]
|
Dec. 31, 2012
Genentech [Member]
|
Dec. 31, 2011
Genentech [Member]
|
Dec. 31, 2013
Genentech [Member]
Profit Sharing Tier One [Member]
|
Dec. 31, 2013
Genentech [Member]
Profit Sharing Tier Two [Member]
|
Oct. 31, 2002
Glaxo SmithKline [Member]
|
Dec. 31, 2013
Glaxo SmithKline [Member]
|
Dec. 31, 2012
Glaxo SmithKline [Member]
|
Dec. 31, 2011
Glaxo SmithKline [Member]
|
Oct. 31, 2011
Glaxo SmithKline [Member]
|
Jul. 31, 2011
Bristol-Myers Squibb [Member]
ROR Collaboration Agreement [Member]
|
Nov. 30, 2010
Bristol-Myers Squibb [Member]
ROR Collaboration Agreement [Member]
|
Dec. 31, 2013
Bristol-Myers Squibb [Member]
ROR Collaboration Agreement [Member]
|
Dec. 31, 2012
Bristol-Myers Squibb [Member]
ROR Collaboration Agreement [Member]
|
Dec. 31, 2011
Bristol-Myers Squibb [Member]
ROR Collaboration Agreement [Member]
|
Nov. 30, 2010
Bristol-Myers Squibb [Member]
TGR5 License Agreement [Member]
|
Jan. 31, 2010
Bristol-Myers Squibb [Member]
LXR Collaboration [Member]
|
Jan. 31, 2009
Bristol-Myers Squibb [Member]
LXR Collaboration [Member]
|
Dec. 31, 2007
Bristol-Myers Squibb [Member]
LXR Collaboration [Member]
|
Dec. 31, 2005
Bristol-Myers Squibb [Member]
LXR Collaboration [Member]
|
Dec. 31, 2013
Bristol-Myers Squibb [Member]
LXR Collaboration [Member]
product
|
Dec. 31, 2013
Bristol-Myers Squibb [Member]
Terminated Collaborations [Member] [Member]
|
Dec. 31, 2012
Bristol-Myers Squibb [Member]
Terminated Collaborations [Member] [Member]
|
Dec. 31, 2011
Bristol-Myers Squibb [Member]
Terminated Collaborations [Member] [Member]
|
|
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||||||||||||||
Upfront and milestone payments | $ 15,000,000.0 | $ 25,000,000.0 | $ 65,000,000.0 | |||||||||||||||||||||||||||||
Payment to use exercise of option related to co-development agreement | 3,000,000.0 | |||||||||||||||||||||||||||||||
Milestone payment | 7,000,000.0 | |||||||||||||||||||||||||||||||
Percent of profits | 50.00% | 30.00% | ||||||||||||||||||||||||||||||
Profit threshold | 200,000,000 | 400,000,000 | ||||||||||||||||||||||||||||||
Optional percent of total sales | 25.00% | |||||||||||||||||||||||||||||||
Maximum Potential Milestone Payments | 2,400,000,000 | |||||||||||||||||||||||||||||||
Percentage of Maximum Potential Milestone Payments - Clinical Development | 10.00% | |||||||||||||||||||||||||||||||
Percentage of Maximum Potential Milestone Payments - Regulatory | 41.00% | |||||||||||||||||||||||||||||||
Percentage of Maximum Potential Milestone Payments - Commercial | 49.00% | |||||||||||||||||||||||||||||||
Research and development funding and loan | 85,000,000.0 | |||||||||||||||||||||||||||||||
Common stock, shares issued | 184,533,651 | 183,697,213 | 3,000,000 | 5,537,906 | ||||||||||||||||||||||||||||
Percent of royalty on net sale | 3.00% | |||||||||||||||||||||||||||||||
Royalty Expense | 400,000 | |||||||||||||||||||||||||||||||
Upfront cash payment | 5,000,000 | 17,500,000.0 | ||||||||||||||||||||||||||||||
Number of years for initial research | 2 years | |||||||||||||||||||||||||||||||
Maximum amount eligible for development and regulatory milestones | 255,000,000 | 138,000,000 | ||||||||||||||||||||||||||||||
Number of products | 2 | |||||||||||||||||||||||||||||||
Maximum amount eligible for royalties on sales under collaborations agreement | 225,000,000.0 | |||||||||||||||||||||||||||||||
Income from development milestone | 2,500,000.0 | 5,000,000.0 | ||||||||||||||||||||||||||||||
Maximum amount eligible for commercial milestones under collaborations agreement | 150,000,000 | |||||||||||||||||||||||||||||||
License, contract and collaboration reimbursement revenues | 16,321,000 | 47,450,000 | 289,636,000 | 0 | 0 | 0 | 0 | 0 | 0 | 1,500,000 | 2,900,000 | 2,800,000 | 14,800,000 | 28,400,000 | 168,900,000 | |||||||||||||||||
Additional research fund | 7,700,000 | |||||||||||||||||||||||||||||||
Research and development fund | $ 5,800,000 | $ 10,000,000.0 |